Ms. Shirley Wu resigned from the Board of Directors of Nature's Sunshine Products, Inc. effective May 31, 2022. Ms. Wu had been designated for appointment to the Company's Board of Directors by Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (“Fosun”) pursuant to the Stockholder Agreement between Fosun and the Company dated June 26, 2014.

Ms. Wu's decision to resign is not due to any disagreement with the Company, including with respect to any matter relating to the Company's operations, policies or practices. Effective June 1, 2022, the Company's Board of Directors appointed Mr. Rong Yang to its Board of Directors. Mr. Yang was designated by Fosun and appointed to serve as a director until the next shareholders' meeting at which directors are elected.

Mr. Yang currently serves as CEO of Fosun Pharma USA Inc. and Chief Representative of the Fosun Group in the United States, a position he has held since January 2022. Prior to joining Fosun, Mr. Yang held various senior positions with Bayer US LLC for nearly 20 years, including Vice President, Head of Specialty Sales with Bayer US; Vice President of Business Insight US; and Vice President of Finance and Strategy Americas. Mr. Yang holds a Bachelor's degree from Beijing Foreign Studies University, a Master of Economics from Nankai University, and a Masters of Business Administration from Harvard University.

The Board of Directors determined that Mr. Yang is an independent director under the current standards for independence established by NASDAQ. In making this determination, the Board of Directors considered Mr. Yang's affiliation with Fosun, one of the Company's shareholders.